Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Brain Neoplasms 1

Interventions

obinutuzumab 2ofatumumab 1milatuzumab 1ibrutinib 1fenebrutinib 1abexinostat 1RO6839921 1KW-2478 1Interleukin-15 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Bronchiolitis Obliterans Syndrome × Interleukin-15 × Clear all
NCT03759184 2022-03-22

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 13 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡